News
1d
GlobalData on MSNAstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trialThe trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.
The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...
AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...
AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...
AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...
In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...
The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...
AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG ...
Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results